11/8
12:31 pm
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Medium
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.